Would you wear an insulin pump if it had no tubing to catch on a doorknob? Tandem Diabetes Care now says the FDA cleared that option for its Mobi pump. The company announced the clearance on November 13, 2026, and Healio and Mugglehead reported the same news. What is verified: Tandem’s own release, plus those two outlets. What is not: the clearance date, the 510(k) number and any study data, none of which the pages I opened provided.
A Mobi Pump With a Tubeless Option
The Mobi is a small insulin pump. Until now, it connected to the body through a thin tube and an infusion set. Tandem says the new tubeless cartridge and infusion set let people wear the pump directly on the body instead. Tandem describes it as the world’s first and only tubeless automated insulin delivery system with up to seven days of wear. That “first and only” wording is the company’s claim, not one I could confirm independently.
Here is how the wear times break down, according to Tandem’s release. The infusion set can stay on for up to seven days. The insulin cartridge lasts three days. The tubed version stays available, so people can choose either style.
Tandem also says people already using a Mobi under warranty will not need a new pump. They would need the new supplies.
What Control-IQ+ Does Behind the Scenes
The pump runs Tandem’s Control-IQ+ software. It reads data from a compatible continuous glucose monitor, which is a sensor that checks glucose under the skin. Tandem says the software predicts glucose 30 minutes ahead and adjusts insulin to match. This is called automated insulin delivery, or a hybrid closed loop. It still needs a person to take part in their own care.
Tandem’s safety information lists the labeled uses. Control-IQ+ is labeled for type 1 diabetes from age 2 and for type 2 diabetes from age 18. The pump is prescription only.
Where It Fits Among Other Pumps
Mugglehead notes the competition. Insulet’s Omnipod 5 is tubeless and lasts up to three days per pod, according to that report. It also mentions a MiniMed extended infusion set that can last up to seven days. So the seven-day claim is not unique on its own. Tandem is pairing it with a tubeless design on a pump people may already own. For another look at insulin data on a wrist, see our piece on Pixel Watch insulin trends.
Limits and Open Questions
The company release cites no clinical trial and no sample size for the tubeless supplies. Healio and Mugglehead cite none either. Price is not stated. Neither is a specific CGM brand, beyond the term “compatible interoperable” sensors.
Tandem’s safety section says Control-IQ+ should not be used by children under 2, by people who need less than five units of insulin a day, or by anyone under 20 pounds. Poor use can still lead to low or high blood sugar. Tandem also warns that its launch could be delayed by scaling and infrastructure challenges.
A TipRanks item says the clearance came on November 12. Tandem’s release gives no date, so I am not relying on that. I also could not find the FDA database entry. For a similar case where a clearance came without accuracy figures, see our post on a cleared brain aneurysm AI tool. This post is general information, not medical advice.
Why It Matters to You
- Not available yet. Tandem plans a full U.S. launch in the first half of 2027.
- Pharmacy only. Tandem says it will sell the tubeless supplies through the pharmacy benefit, which it estimates covers about half of insured U.S. lives. Your plan may differ.
- Choice, not a replacement. Tubed and tubeless wear will both be cleared on the same pump.
If you or a family member uses a pump, ask your care team a plain question. Would a tubeless set suit my skin, my activity and my coverage?
Sources
- Tandem Diabetes Care, company press release, November 13, 2026
- Healio (Endocrine Today), November 13, 2026
- Mugglehead, November 13, 2026
- TipRanks, company announcements item, updated November 13, 2026
- FDA 510(k) database search page (form only, no Tandem entry reviewed)